Novexel Appoints Chief Financial Officer
News Jan 23, 2006
Novexel has announced the appointment of Gordon Waldron as Chief Financial Officer with immediate effect.
Gordon joins Novexel from the French biotechnology company Synt:em S.A., where he held the position of Vice President Finance & CFO from 1997.
During this time he built a pan-European, blue chip investor base, raised €30 million in private equity financing, negotiated a technology out licensing deal with a US public biotech company and ultimately the sale of Synt:em to a private French pharmaceutical company.
Prior to Synt:em, Gordon was Group Finance Manager for Europe, Africa and Middle East at Texas Instruments Software in the UK, which involved Group Financial and Management Accounting for 17 legal entities and a distributor network across 14 countries.
During this time, Gordon participated in negotiations for various MBO/entity disposal projects.
Gordon also worked for the Paris branch of Texas Instruments Software where he was Finance Director of their start-up subsidiary.
Previously, Gordon held Controller positions at Spie Batignolles in both the US and France.
Iain Buchanan, CEO of Novexel, commented, "I am delighted to welcome Gordon to Novexel in this key role. His breadth of financial experience will be of tremendous value as we continue to build the Company in 2006 and beyond."
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE